首页> The oncologist> A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Johanna C,Bendell

第一单位： Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA jbendell@tnonc.com.

作者： Johanna C,Bendell ^[1] ; Howard,Hochster ^[2] ; Lowell L,Hart ^[3] ; Irfan,Firdaus ^[4] ; Joseph R,Mace ^[5] ; Joshua J,McFarlane ^[6] ; Mark,Kozloff ^[7] ; Daniel,Catenacci ^[7] ; Jessie J,Hsu ^[8] ; Stephen P,Hack ^[8] ; David S,Shames ^[8] ; See-Chun,Phan ^[8] ; Hartmut,Koeppen ^[8] ; Allen L,Cohn ^[9]

作者单位： Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA jbendell@tnonc.com. ^[1] Yale School of Medicine, New Haven, Connecticut, USA. ^[2] Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, Florida, USA. ^[3] Sarah Cannon Research Institute/Oncology Hematology Care, Cincinnati, Ohio, USA. ^[4] Sarah Cannon Research Institute/Florida Cancer Specialists, St Petersburg, Florida, USA. ^[5] Sarah Cannon Research Institute/Virginia Cancer Institute, Richmond, Virginia, USA. ^[6] University of Chicago, Chicago, Illinois, USA. ^[7] Genentech Inc., South San Francisco, California, USA. ^[8] Rocky Mountain Cancer Center, Denver, Colorado, USA. ^[9]

关键词 Bevacizumb FOLFOX Metastatic colorectal cancer Onartuzumab Phase II Randomized